NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

The trouble is, it's a human trait to want to satisfy people and tell them what they want to hear.
And if you are in IR, it's almost obligatory.

DI is not about to start shareholders; 'everything is on hold, we're down to our last dime, might be a good time to sell your shares'.

So he will always be inclined to intimate that something good is just around the corner. And that's the nature of an IR job.
Whoever is in those shoes is likely to communicate in the same way.

Last years ASM was a case in point. I think it was JJ who stated that the coming year was looking good (or something similar).
And the majority of shareholders seemed to come away from that with a bit of renewed confidence.
But a year on, I guess, for at least some, that feeling has dissipated somewhat (or gone completely for others!)

They do need to tweak the overpromise/underdeliver ratio a bit towards underpromise and maybe occasionally overdeliver, and I think they themselves know that.

And let's face it, everybody knows they simply haven't got the resources to actually commence a Direct P2.

They got the rGBM trial using Keytruda going, because it's largely SPORE funded. Which means it's not really their trial and the DC vaccine can't be called DCVax-L. And there are unanswered questions about data ownership rights. If the non-Keytruda arm proves superior (which is likely, imo), Merck is not going to want li'l old NWBO trumpeting the results everywhere...

So near enough everything they say on future trial possibilities should be prefaced with a 'when resources allow'.
I still want to hear that they have the ambition to move to new trials as and when. Basically, what is the scientific plan going forward.
So tell us that they are still ambitious, but don't give timescales that can't be kept.

Just my opinion.